In addition to Tylenol, Kenvue production facilities roll out essential name-brand health products like Neosporin, Motrin and BAND-AID.

Texas Attorney General Ken Paxton on Thursday asked a state judge to block Kenvue from paying a nearly $400 million ...

More Ebitda means more dividends—and both companies already have a stellar track record of cash returns. Kimberly-Clark and ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer ...

In one of the most significant consumer-goods mergers of the year, Kimberly-Clark is buying Tylenol maker Kenvue in a ...

The recent publicity could allow the company to get a good deal on Kenvue, which makes Tylenol, Band-Aids, and other ...

IP, M&A, life sciences and competition partners advised on deal that brings together brands such as ‘Huggies’ and ‘Kleenex’ ...

A price-sensitive, value-conscious consumer adds a degree of unevenness and uncertainty to a robust earnings season.

Kleenex maker Kimberly-Clark will buy Kenvue at a 46% premium, tanking its own stock by 13%. Synergies promise a decent return to numb the pain of a high price. It’s an opportunistic bet that claims ...

It pays a semiannual dividend and yields 4.4% based on the two most recent payments. Morningstar Equity analysts note that the firm pays out roughly 50% of its earnings as dividends, which is about ...

Kimberly-Clark, the maker of Huggies, said Monday it will acquire Kenvue, Tylenol’s parent, in a cash-and-stock transaction valued at nearly $50 billion. The companies said the combined portfolio will ...